Group 1 - The core point of the article is that Hantian Technology (Xiamen) Co., Ltd. has seen its Hong Kong IPO application expire after six months, with CICC serving as the sole sponsor during the application process [1] - Hantian Technology is recognized as a leader and innovator in the global silicon carbide (SiC) epitaxy industry [2] - According to a report by Zhi Shi Consulting, Hantian Technology is the largest supplier of silicon carbide epitaxy globally in terms of sales volume since 2023, with a market share exceeding 30% in 2024 [2]

瀚天天成电子科技(厦门)股份有限公司(简称：瀚天天成)于4月8日所递交的港股招股书满6个月，于10月8日失效，递表时中金公司（601995）为独家保荐 人。 招股书显示，瀚天天成是全球碳化硅(SiC)外延行业的领导者和革新者。根据灼识咨询的报告，自2023年来，按年销售片数计，瀚天天成是全球最大的碳化 硅外延供应商，2024年的市场份额超过30%。 ...

Group 1 - The China Securities Regulatory Commission (CSRC) has published supplementary material requirements for overseas issuance and listing, specifically requesting information from Hantian Tiancheng regarding its previous A-share listing guidance and the reasons for termination, as well as plans for continuing A-share listing efforts [1] - Hantian Tiancheng has submitted an application for listing on the Hong Kong Stock Exchange, with China International Capital Corporation (CICC) as the sole sponsor [1] - The CSRC requires clarification on the relationship between new shareholders and the company's directors, as well as any potential conflicts of interest, and the progress of state-owned asset management procedures [1] Group 2 - Hantian Tiancheng is recognized as a leader and innovator in the global silicon carbide (SiC) epitaxy industry, being the largest supplier of SiC epitaxy by sales volume since 2023, with a market share exceeding 30% in 2024 according to a report by ZhiShi Consulting [2]

Group 1: New Listings and Filings - Five companies submitted applications for listing on the Hong Kong Stock Exchange from April 7 to April 13, 2023 [2] - Hantian Technology (Xiamen) Co., Ltd. is a global leader in the silicon carbide (SiC) epitaxy industry, with a projected market share exceeding 30% in 2024 [2] - IFBH Limited, a rapidly growing beverage and food company based in Thailand, has a market share of approximately 34% in the coconut water market in mainland China for 2024 [3] - Jihong Co., Ltd. focuses on cross-border social e-commerce and packaging solutions, ranking second in the B2C export e-commerce sector in China with a market share of 1.3% [3] - Jiangxi Biological Products Research Institute is the largest provider of human tetanus antitoxin in China, with a market share of 65.8% in 2024 [4] Group 2: Financial Performance - Hantian Technology's projected revenues for 2022, 2023, and 2024 are approximately RMB 441 million, RMB 1.143 billion, and RMB 974 million, respectively [2] - IFBH Limited's revenues for 2023 and 2024 are expected to be approximately RMB 87.44 million and about USD 158 million, with net profits of RMB 16.75 million and USD 33.32 million [3] - Jihong Co., Ltd. anticipates revenues of approximately RMB 5.376 billion, RMB 6.695 billion, and RMB 5.529 billion for 2022, 2023, and 2024, respectively [3] - Jiangxi Biological's projected revenues for 2022, 2023, and 2024 are approximately RMB 142 million, RMB 198 million, and RMB 221 million, respectively [4] - Ming Kee Hospital Group, the largest private hospital group in East China, expects revenues of approximately RMB 2.336 billion, RMB 2.688 billion, and RMB 2.659 billion for 2022, 2023, and 2024 [5] Group 3: Upcoming IPOs - Zhengli New Energy plans to offer 121.5 million H-shares at an IPO price of HKD 8.27, with net proceeds of HKD 928 million [5] - Ying'en Biotechnology-B is set to offer 15.0716 million shares with a price range of HKD 94.6 to HKD 103.2, expected to start trading on April 15, 2025 [6]